Cargando…

Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease

OBJECTIVE: History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19. METHODS: We included 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Tessitore, Elena, Carballo, David, Poncet, Antoine, Perrin, Nils, Follonier, Cedric, Assouline, Benjamin, Carballo, Sebastian, Girardin, François, Mach, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039226/
https://www.ncbi.nlm.nih.gov/pubmed/33833064
http://dx.doi.org/10.1136/openhrt-2020-001526
_version_ 1783677543989116928
author Tessitore, Elena
Carballo, David
Poncet, Antoine
Perrin, Nils
Follonier, Cedric
Assouline, Benjamin
Carballo, Sebastian
Girardin, François
Mach, Francois
author_facet Tessitore, Elena
Carballo, David
Poncet, Antoine
Perrin, Nils
Follonier, Cedric
Assouline, Benjamin
Carballo, Sebastian
Girardin, François
Mach, Francois
author_sort Tessitore, Elena
collection PubMed
description OBJECTIVE: History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19. METHODS: We included 839 patients with COVID-19 hospitalised at the University Hospitals of Geneva. Demographic characteristics, medical history, laboratory values, ECG at admission and medications at admission were collected based on electronic medical records. The primary outcome was a composite of in-hospital mortality or MACE. RESULTS: Median age was 67 years, 453 (54%) were males and 277 (33%) had history of CVD. In total, 152 (18%) died and 687 (82%) were discharged, including 72 (9%) who survived a MACE. Patients with previous CVD were more at risk of composite outcomes 141/277 (51%) compared with those without CVD 83/562 (15%) (OR=6.0 (95% CI 4.3 to 8.4), p<0.001). Multivariate analyses showed that history of CVD remained an independent risk factor of in-hospital death or MACE (OR=2.4; (95% CI 1.6 to 3.5)), as did age (OR for a 10-year increase=2.2 (95% CI 1.9 to 2.6)), male gender (OR=1.6 (95% CI 1.1 to 2.3)), chronic obstructive pulmonary disease (OR=2.1 (95% CI 1.0 to 4.2)) and lung infiltration associated with COVID-19 at CT scan (OR=1.9 (95% CI 1.2 to 3.0)). History of CVD (OR=2.9 (95% CI 1.7 to 5)), age (OR=2.5 (95% CI 2.0 to 3.2)), male gender (OR=1.6 (95% CI 0.98 to 2.6)) and elevated C reactive protein (CRP) levels on admission (OR for a 10 mg/L increase=1.1 (95% CI 1.1 to 1.2)) were independent risk factors for mortality. CONCLUSION: History of CVD is associated with higher in-hospital mortality and MACE in hospitalised patients with COVID-19. Other factors associated with higher in-hospital mortality are older age, male sex and elevated CRP on admission.
format Online
Article
Text
id pubmed-8039226
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80392262021-04-13 Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease Tessitore, Elena Carballo, David Poncet, Antoine Perrin, Nils Follonier, Cedric Assouline, Benjamin Carballo, Sebastian Girardin, François Mach, Francois Open Heart Cardiac Risk Factors and Prevention OBJECTIVE: History of cardiovascular diseases (CVDs) may influence the prognosis of patients hospitalised for COVID-19. We investigated whether patients with previous CVD have increased risk of death and major adverse cardiovascular event (MACE) when hospitalised for COVID-19. METHODS: We included 839 patients with COVID-19 hospitalised at the University Hospitals of Geneva. Demographic characteristics, medical history, laboratory values, ECG at admission and medications at admission were collected based on electronic medical records. The primary outcome was a composite of in-hospital mortality or MACE. RESULTS: Median age was 67 years, 453 (54%) were males and 277 (33%) had history of CVD. In total, 152 (18%) died and 687 (82%) were discharged, including 72 (9%) who survived a MACE. Patients with previous CVD were more at risk of composite outcomes 141/277 (51%) compared with those without CVD 83/562 (15%) (OR=6.0 (95% CI 4.3 to 8.4), p<0.001). Multivariate analyses showed that history of CVD remained an independent risk factor of in-hospital death or MACE (OR=2.4; (95% CI 1.6 to 3.5)), as did age (OR for a 10-year increase=2.2 (95% CI 1.9 to 2.6)), male gender (OR=1.6 (95% CI 1.1 to 2.3)), chronic obstructive pulmonary disease (OR=2.1 (95% CI 1.0 to 4.2)) and lung infiltration associated with COVID-19 at CT scan (OR=1.9 (95% CI 1.2 to 3.0)). History of CVD (OR=2.9 (95% CI 1.7 to 5)), age (OR=2.5 (95% CI 2.0 to 3.2)), male gender (OR=1.6 (95% CI 0.98 to 2.6)) and elevated C reactive protein (CRP) levels on admission (OR for a 10 mg/L increase=1.1 (95% CI 1.1 to 1.2)) were independent risk factors for mortality. CONCLUSION: History of CVD is associated with higher in-hospital mortality and MACE in hospitalised patients with COVID-19. Other factors associated with higher in-hospital mortality are older age, male sex and elevated CRP on admission. BMJ Publishing Group 2021-04-08 /pmc/articles/PMC8039226/ /pubmed/33833064 http://dx.doi.org/10.1136/openhrt-2020-001526 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cardiac Risk Factors and Prevention
Tessitore, Elena
Carballo, David
Poncet, Antoine
Perrin, Nils
Follonier, Cedric
Assouline, Benjamin
Carballo, Sebastian
Girardin, François
Mach, Francois
Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
title Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
title_full Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
title_fullStr Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
title_full_unstemmed Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
title_short Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease
title_sort mortality and high risk of major adverse events in patients with covid-19 and history of cardiovascular disease
topic Cardiac Risk Factors and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039226/
https://www.ncbi.nlm.nih.gov/pubmed/33833064
http://dx.doi.org/10.1136/openhrt-2020-001526
work_keys_str_mv AT tessitoreelena mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT carballodavid mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT poncetantoine mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT perrinnils mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT folloniercedric mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT assoulinebenjamin mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT carballosebastian mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT girardinfrancois mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease
AT machfrancois mortalityandhighriskofmajoradverseeventsinpatientswithcovid19andhistoryofcardiovasculardisease